Curanex Pharmaceuticals Inc
CURX
$0.31
$0.000.07%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -2.17% | 240.41% | |||
| Gross Profit | 2.17% | -240.41% | |||
| SG&A Expenses | 17.92% | 187.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.94% | 225.09% | |||
| Operating Income | -2.94% | -225.09% | |||
| Income Before Tax | -2.51% | -222.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.51% | -222.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.51% | -222.09% | |||
| EBIT | -2.94% | -225.09% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -2.59% | -190.35% | |||
| Normalized Basic EPS | -2.66% | -190.56% | |||
| EPS Diluted | -2.59% | -190.35% | |||
| Normalized Diluted EPS | -2.66% | -190.56% | |||
| Average Basic Shares Outstanding | -0.10% | 10.83% | |||
| Average Diluted Shares Outstanding | -0.10% | 10.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||